Sanjivani Paranteral Ltd.

BSE: SANJIVIN531569ISIN INE860D01013

Healthcare
Pharmaceuticals

Share price

₹173.55+5.90 (+3.52%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹244.00
52W low: ₹126.00
Off 52W high: -28.87%
1M return: +4.58%
3M return: -9.37%
6M return: +4.49%
1Y return: -18.25%
20D avg volume: 7,968
50 DMA: ₹176.32
200 DMA: ₹168.51

Key ratios Consolidated

Market cap: ₹213.19 Cr
Current price: ₹173.55
52W high / low: ₹244.00 / ₹126.00
Face value: ₹10.00
P/E: 20.39
P/B: 4.42
EPS (TTM): ₹8.51
Book value / share: ₹39.27
ROE: —
ROCE: 16.50%
Operating margin: —
Net margin: —
Debt / equity: 0.28
Net debt: ₹13.04 Cr
Interest cover: 12.89
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 120.9 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q4 FY24
Income statement
	23.84	13.21	22.06	18.50	17.89	18.18	17.35	18.13	—
	0.15	0.60	0.30	0.16	0.04	0.43	0.31	0.39	—
	23.99	13.81	22.36	18.66	17.93	18.61	17.66	18.52	—
	20.67	12.61	18.66	13.47	15.63	15.96	15.15	15.60	—
	15.67	7.45	14.02	10.66	11.40	9.61	10.11	6.24	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	2.35	2.24	1.76	1.49	1.52	2.11	1.65	1.61	—
	0.35	0.31	0.21	0.05	0.22	0.20	0.19	0.18	—
	0.65	0.66	0.23	0.17	0.16	0.18	0.16	0.15	—
	2.39	2.00	1.73	1.42	2.61	4.07	3.22	—	—
	3.32	1.20	3.70	5.19	2.30	2.65	2.51	2.92	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	3.32	1.20	3.70	5.19	2.30	2.65	2.51	2.92	—
	0.83	0.65	0.92	0.55	0.57	0.47	0.61	0.62	—
	2.49	0.55	2.78	4.64	1.73	2.19	1.90	2.30	—
	2.03	0.49	2.21	3.78	1.46	1.84	1.62	1.96	—
Key metrics
	4.32	2.17	4.14	5.41	2.68	3.03	2.86	3.25	—
	18.10%	16.40%	18.80%	29.20%	15.00%	16.70%	16.50%	17.90%	—
	10.40%	4.20%	12.60%	25.10%	9.70%	12.00%	11.00%	12.70%	—
	—	2.50%	—	9.80%	—	6.10%	—	—	—
	33.30%	-27.30%	27.10%	2.00%	—	—	—	—	—
	43.90%	-74.90%	46.30%	101.70%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	77.61	68.67	70.10	—
	1.21	1.09	1.22	—
	78.82	69.76	71.31	—
	65.41	60.36	60.96	—
	47.80	43.53	33.56	—
	0.00	0.00	0.00	—
	7.84	7.01	6.49	—
	0.92	0.79	0.59	—
	1.71	1.22	0.62	—
	7.54	7.77	12.77	—
	13.41	9.39	10.35	—
	0.00	0.00	0.00	—
	13.41	9.39	10.35	—
	2.95	2.70	2.26	—
	10.46	6.69	8.09	—
	8.51	5.49	6.89	—
Key metrics
	16.04	11.40	11.56	—
	20.67%	16.60%	16.50%	—
	13.48%	9.70%	11.50%	—
	—	16.50%	23.60%	—
	8.47%	-2.00%	—	—
	28.82%	-17.30%	—	—
	—	-8.70	-17.95	—
	—	0.00	1.53	—
	—	0.28	0.20	—
	—	13.04	6.65	—
	—	120.9	62.2	—
Balance sheet
	—	87.97	78.20	—
	—	36.40	34.18	—
	—	1.24	1.49	—
	—	15.43	16.68	—
	—	11.02	10.51	—
	—	—	0.00	—
	—	46.92	20.56	—
	—	3.70	15.25	—
	—	26.39	31.79	—
	—	14.28	8.14	—
	—	5.71	2.85	—
	—	8.57	5.29	—
	—	50.84	39.87	—
Cash flow
	—	0.03	12.40	—
	—	-9.97	-20.11	—
	—	9.70	8.66	—
	—	8.73	30.35	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	19.46	10.51	20.86	15.50	17.89	18.18	17.35	18.13	16.44	—
	0.15	0.75	0.29	0.16	0.04	0.43	0.31	0.39	0.09	—
	19.61	11.26	21.15	15.66	17.93	18.61	17.66	18.52	16.52	—
	16.55	10.01	17.67	13.47	15.63	15.95	15.15	15.60	14.25	—
	12.91	6.17	13.41	10.66	11.40	9.61	10.11	6.24	7.60	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	1.75	1.69	1.62	1.49	1.52	2.11	1.65	1.61	1.13	—
	0.18	0.06	0.21	0.05	0.22	0.20	0.19	0.18	0.02	—
	0.31	0.35	0.19	0.17	0.16	0.18	0.16	0.15	0.13	—
	1.81	1.62	1.46	1.42	2.61	4.06	3.22	—	2.71	—
	3.06	1.25	3.49	2.19	2.30	2.66	2.51	2.92	2.27	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	3.06	1.25	3.49	2.19	2.30	2.66	2.51	2.92	2.27	—
	0.77	0.31	0.87	0.55	0.57	0.47	0.61	0.62	0.56	—
	2.30	0.94	2.62	1.64	1.73	2.19	1.90	2.30	1.71	—
	1.87	0.80	2.13	1.33	1.46	1.84	1.62	1.96	1.47	—
Key metrics
	3.55	1.66	3.89	2.41	2.68	3.04	2.86	3.25	2.42	—
	18.20%	15.80%	18.60%	15.50%	15.00%	16.70%	16.50%	17.90%	14.70%	—
	11.80%	8.90%	12.60%	10.60%	9.70%	12.00%	11.00%	12.70%	10.40%	—
	—	2.30%	—	4.40%	—	6.40%	—	—	—	—
	8.80%	-42.20%	20.20%	-14.50%	8.80%	—	—	—	—	—
	32.90%	-57.10%	37.90%	-28.70%	1.20%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	66.33	64.76	70.10	—
	1.35	1.24	1.21	—
	67.68	66.00	71.31	—
	57.70	56.77	60.95	—
	43.15	41.65	33.56	—
	0.00	0.00	0.00	—
	6.55	6.33	6.49	—
	0.50	0.54	0.59	—
	1.02	0.86	0.62	—
	6.31	7.11	12.76	—
	9.99	9.23	10.36	—
	0.00	0.00	0.00	—
	9.99	9.23	10.36	—
	2.50	2.31	2.26	—
	7.50	6.92	8.10	—
	6.13	5.67	6.89	—
Key metrics
	11.51	10.63	11.57	—
	17.35%	16.40%	16.50%	—
	11.31%	10.70%	11.60%	—
	—	17.20%	24.60%	—
	-7.30%	-7.60%	—	—
	-7.64%	-14.60%	—	—
	—	-4.17	-11.48	—
	—	-0.22	-0.03	—
	—	0.19	0.15	—
	—	8.00	5.00	—
	—	50.3	61.8	—
Balance sheet
	—	78.43	65.00	—
	—	48.28	38.10	—
	—	1.15	0.63	—
	—	11.01	16.68	—
	—	9.54	10.42	—
	—	1.11	0.00	—
	—	22.05	20.56	—
	—	11.64	15.25	—
	—	21.58	20.46	—
	—	9.15	5.63	—
	—	2.48	0.34	—
	—	6.67	5.29	—
	—	48.39	38.00	—
Cash flow
	—	-1.55	-0.24	—
	—	-4.47	-5.81	—
	—	6.54	6.14	—
	—	2.62	11.24	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -7.30%
Profit YoY (TTM): -7.64%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +8.47%
Profit YoY (TTM): +28.82%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 31.57%

Quarter	September 2026	June 2026
Promoter %	31.57%	31.57%

Holder	Type	Holding	Previous	Change
ASHWANI ANAMISHARAN KHEMKA	Promoter	29.88%	—	—
SURESH PUKHRAJ JAIN	Public	6.50%	7.05%	-0.55%
KANTA SURESH JAIN	Public	6.01%	6.01%	0.00%
INDIA EQUITY FUND 1	Public	4.90%	4.97%	-0.07%
1	Public	4.39%	—	—
USHA RAVINDRA BHAT	Public	3.07%	2.66%	+0.41%
ASHISH KACHOLIA	Public	3.01%	3.01%	0.00%
AJAY UPADHYAYA	Public	1.90%	—	—
NAINA KHEMKA	Promoter	1.69%	1.69%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Sanjivani Paranteral Ltd.	213	173.55	20.39	16.50%	+8.47% TTM	+28.82% TTM	-18.25%

Filings & corporate actions

Recent announcements

Sanjivani Paranteral Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve 1. To approve the Un-Audited ....29 Oct 2026 · Board Meeting / Board Meeting
Regulation 74(5) for the quarter end 30th September, 202614 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for the Second Quarter and Half Year Ended, 30th September, 202628 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Closure of Trading Window for the Quarter ended 30th September, 202628 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Disclosure under regulation 3023 Sep 2026 · Company Update / General
Scrutinizer Report for the Annual General Meeting held on 16th September, 202616 Sep 2026 · AGM/EGM / AGM
Proceeding and Outcome of 32nd Annual General Meeting of the Company16 Sep 2026 · AGM/EGM / AGM
Newspaper Advertisment of 32nd Annual general Meeting notice In accordance with Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.26 Aug 2026 · Company Update / Newspaper Publication
Record Date for AGM24 Aug 2026 · Corp. Action / Record Date
Book Closure for AGM24 Aug 2026 · Corp. Action / Book Closure
Notice of AGM for FY 2025-2624 Aug 2026 · AGM/EGM / AGM
Annual Report of Financial Year 2025-2624 Aug 2026 · Others / Reg. 34 (1) Annual Report
Postal ballot Outcome24 Aug 2026 · AGM/EGM / Postal Ballot
Postal Ballot Outcome24 Aug 2026 · AGM/EGM / Postal Ballot
Newspaper Advertisment of Unaudited Financial results for the First Quarter Ended 30th June, 2026 pursuant to Regulation 30 read with Regulation 47 of SEBI (Listing Obligations and Disclosures ....17 Aug 2026 · Company Update / Newspaper Publication
Quarter ended 30th June, 202614 Aug 2026 · Company Update / Press Release / Media Release
Quarter ended 30th June, 202614 Aug 2026 · Company Update / Investor Presentation
Outcome of Board Meeting held on Friday, 14th August, 202614 Aug 2026 · Board Meeting / Outcome of Board Meeting
Finacials Results for the Quarter ended 30th June, 202614 Aug 2026 · Result / Financial Results
Sanjivani Paranteral Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve 1. To consider and approve ....10 Aug 2026 · Board Meeting / Board Meeting
News Paper Advertisment of Postal Ballot Notice of Sanjivani Paranteral Limited, pursuant to regulation 47 of Securities and Exchange Board of India (Listing Obligation and Disclosures ....27 Jul 2026 · Company Update / Newspaper Publication
Notice of Postal ballot dated 23rd July, 2026 of the Company23 Jul 2026 · AGM/EGM / Postal Ballot
As per Attachment23 Jul 2026 · Company Update / Preferential Issue
As per attachement23 Jul 2026 · Board Meeting / Outcome of Board Meeting
Sanjivani Paranteral Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2026 ,inter alia, to consider and approve 1. To consider and discuss ....20 Jul 2026 · Board Meeting / Board Meeting
Certificate under Reg. 75(5) of SEBI (DP) Regulations for the Quarter ended on 30.06.20269 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for the Quarter ended 30th June, 202625 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashwani Khemka25 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashwani Khemka11 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Annual Secretarial Compliance Report for the financial year ended 31st March, 202629 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), ....21 May 2026 · Board Meeting / Outcome of Board Meeting
Earnings call Transcript as on dated 15th May, 202620 May 2026 · Company Update / Earnings Call Transcript
As per Attached Document.16 May 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the earnings call with analysts and investors held on 15th ....16 May 2026 · Company Update / Analyst / Investor Meet
As per attached Document15 May 2026 · Company Update / Press Release / Media Release
Sanjivani Paranteral Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve the proposal for raising ....15 May 2026 · Board Meeting / Board Meeting
Refer attached document14 May 2026 · Company Update / Investor Presentation
Refer attached document14 May 2026 · Result / Financial Results
Refer attached document14 May 2026 · Board Meeting / Outcome of Board Meeting
Refer attached document12 May 2026 · Company Update / Analyst / Investor Meet

Corporate actions

Purpose	Ex date	Record date	Payment date
Dividend - Rs. - 0.5000	19 Sep 2025	19 Sep 2025	—

Board meetings

5 Nov 2026 Board Meeting - Financial Results
14 Aug 2026 Board Meeting - Financial Results